[RESEARCH BLOG] · 2026-09-11
Monopar Therapeutics Inc. (MNPR) – Sell‑Flip Signal Amid Recovery‑Mode Market Pulse
By Pierre Brunelle · Founder & Research Lead
Monopar Therapeutics Inc. closed on 2026‑09‑10 at $110.0, down 2.15 % from the prior session. The LOPJLB platform has issued a SELL directional signal with a ‑5 score while the broader market regime is flagged as RECOVERY.
Recent Catalysts & News
- Monopar Appoints Jeffrey D. Kent, M.D. – 2026‑08‑19
- Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates – 2026‑08‑12
- Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease – 2026‑07‑22
- Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease – 2026‑06‑30
- Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease – 2026‑06‑26
- Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head‑To‑Head Contrast – 2026‑08‑24
- Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For ‘Strong Buy’ – 2026‑08‑18
- Monopar Therapeutics: ALXN1840’s Bull Case Has Improved – 2026‑07‑03
- Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More – 2026‑08‑13
These items collectively shape the short‑term narrative around Monopar’s pipeline progress, regulatory milestones, and market positioning.
Fundamentals and Valuation
Monopar’s valuation metrics remain deeply negative, reflecting its pre‑revenue, loss‑making status. The trailing twelve‑month (TTM) price‑to‑earnings ratio sits at ‑46.99, while enterprise value‑to‑EBITDA is ‑36.97, both indicating that earnings and cash‑flow generation are currently negative. The price‑to‑book multiple stands at 7.18, suggesting the market is pricing the company well above its book equity, a common feature for biotech firms with promising pipelines but limited tangible assets.
| Metric | Value |
|---|---|
| P/E TTM | ‑46.99 |
| P/B | 7.18 |
| EV/EBITDA | ‑36.97 |
| % of DCF (valuation) | 1 375.9 % |
| ROIC | ‑7.85 % |
| Analyst target price | $123.6 |
| Analyst recommendation | Buy |
Operating margins are effectively zero—gross, operating and net margins are all reported at 0 %, underscoring the absence of product sales. Return on invested capital (ROIC) is ‑7.85 %, and both return on equity (ROE) and return on assets (ROA) are ‑13.08 % and ‑13.22 %, respectively, reflecting the cumulative impact of sustained cash outflows. The company’s debt‑to‑equity ratio is modest at 0.08, indicating limited leverage but also a reliance on equity financing to fund its pipeline.
Historical financials illustrate a pattern of deepening losses and volatile earnings per share (EPS). EPS moved from ‑$0.58 in 2020 to ‑$1.85 in 2025, while free cash flow remained strongly negative, ranging from ‑$4.66 million in 2020 to ‑$12.20 million in 2025. The price‑to‑earnings multiple has fluctuated dramatically, reaching a low of ‑2.94 in 2023 before widening again to ‑35.28 in 2025. These trends highlight the capital‑intensive nature of late‑stage clinical development and the absence of revenue diversification.
The analyst consensus remains Buy, with an average target price of $123.6, implying a modest upside of roughly 12 % from the current $110.0 level. The value score of 8 and growth score of 47 place Monopar in a “Balanced” archetype, indicating that while the company scores modestly on traditional valuation metrics, its growth potential drives a higher composite rating.
ETF Ownership
Monopar’s institutional ownership is relatively thin. Only one exchange‑traded fund holds a material position, with BBC accounting for 1.16 % of the float and ranking fifth among the ETF’s holdings. Concentrated ETF ownership can amplify price movements when the fund rebalances, but the modest size of the stake suggests limited immediate impact on liquidity.
| ETF Ticker | Weight % |
|---|---|
| BBC | 1.16 % |
The limited exposure also means that broader market sentiment, rather than fund‑driven trading, will likely dominate short‑term price dynamics. Investors should monitor any changes in the ETF’s composition, especially if the fund adjusts its exposure in response to evolving clinical milestones or analyst upgrades.
LOPJLB Signal Read
The LOPJLB engine flags MNPR with a SELL directional signal and a ‑5 score while the market is in a RECOVERY regime over the past ten days. Composite performance (PERF) stands at 54.20 and the quality composite (FUND) at 19.00, reflecting a modest quality rating but relatively weak momentum. The stock scores 8 on the value axis, 47 on growth, 6 on GARP, and 19 on quality, landing it in the Balanced archetype.
Readers can explore the interactive chart above for a visual overlay of the signal, and consult the full methodology at the LOPJLB research methodology page.
For a deeper dive into Monopar Therapeutics Inc., visit the dedicated LOPJLB page at lopjlb.com/stock/MNPR. Detailed earnings‑call transcripts (when available) are hosted at lopjlb.com/stock/MNPR/earnings.md, and the broader stock screener can be accessed via lopjlb.com/screener.
The information provided herein is for research purposes only and does not constitute investment advice. All readers should perform their own due diligence and consult professional advisors before making any investment decisions.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.